**Supplementary Tables and Figures**


Supplementary Figure S1 Frequency of SARS-CoV-2 nucleic acid-positive samples from different clinically rated patients. Nucleic acid was purified from COVID-19 patient samples. SARS-CoV-2 was detected by real time RT-PCR with a TaqMan probe. Positive rates of different sample types from different clinically rated patients were calculated and are shown. Sample number is shown in column.

Supplementary Figure S2 Dynamic changes in SARS-CoV-2 nucleic acid-positive rate. Nucleic acid was purified from SARS-CoV-2 nucleic acid-positive patient samples. SARS-CoV-2 was detected by real time RT-PCR with a TaqMan probe. SARS-CoV-2 nucleic acid-positive rates during the first 7 days after hospitalization (<=7), from 7 to 14 days after hospitalization (7~14), from 14 to 28 days after hospitalization (7~28), and from 28 days after hospitalization to recovery (>28) were calculated and are shown. Sample number is shown in column.

Supplementary Figure S3 Diagnosis rate in individuals based on sample type and grouped by clinical manifestation. Nucleic acid was purified from SARS-CoV-2 nucleic acid-positive patient samples. SARS-CoV-2 was detected by real time RT-PCR with a TaqMan probe. Diagnosis rate in individuals based on sample type and grouped by clinical manifestation was calculated and is shown.

Supplementary Figure S4 Anti-SARS-CoV-2 IgM antibody assays in serum of SARS-CoV-2-infected monkeys. Anti-SARS-CoV-2 IgM antibodies in serum of SARS-CoV-2-infected monkeys at 1, 3, 7, 11, 13, and 15 days after infection were detected using a 2019-nCoV IgM antibody detection kit. Representative results are shown. +, positive control. Dashed arrow, internal reference. Solid arrow, anti-IgM antibodies. DAI, days after infection.

Supplementary Table S1 Clinical sample information

Patient No.		1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29
	Nasal[a]	5	4	6	3	11	7	1	2	0	1	0	0	5	2	3	4	4	2	6	5	4	5	2	2	2	2	0	1	0
	Pharyngeal[a]	8	7	7	8	13	11	2	4	2	5	4	3	9	3	10	8	8	4	6	5	4	5	2	2	2	2	1	1	0
	Sputum[b]	4	1	3	6	9	6	0	0	2	3	3	1	4	1	0	6	5	2	3	3	3	3	1	0	1	0	0	2	0
Nucleic acid	Anal[a]	2	1	2	1	7	6	0	0	0	0	0	0	1	0	2	1	1	0	2	0	0	2	0	0	0	0	0	0	0
detection	Fecal[b]	3	2	3	2	5	4	0	0	0	1	0	0	1	0	3	2	1	1	2	3	2	2	0	0	0	1	0	0	0
	Serum[b]	1	0	0	1	0	0	0	1	0	0	2	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0
	Saliva[b]	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	0	0
	Urine[b]	1	1	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	2	1	0	0	0	1	0	0	0
Antibody detection	Serum[b]	3	1	1	3	4	1	2	4	2	3	2	3	3	2	1	2	3	5	5	6	5	6	5	4	5	5	3	3	4
Clinical manifestation		mi	mi	se	mo	mo	as	mo	mi	mo	cr	mi	se	mo	mo	mi	mo	se	se	mi	as	as	mo	mo	mo	mo	mo	mi	mo	mo

a, Swab number. b, Number of samples. mi, mild. as, asymptomatic. mo, moderate. se, severe. cr, critical.

Supplementary Table S2 Sample information on SARS-CoV-2-infected monkeys

Monkey No.		1	2	3	4	5	6	7	8	9	10	11	12	13	14	15
Infection routine		a	a	a	a	a	a	a	a	a	a	a	a	b	b	b
Nucleic acid detection	**Nasal**[c, d]	4	12	4	12	5	13	13	5	15	7	15	7	4	4	4
	Pharyngeal[c, d]	4	12	4	12	5	13	13	5	15	7	15	7	4	4	4
	Anal[c, d]	4	12	4	12	5	13	13	5	15	7	15	7	4	4	4
	Tracheal brush[d]	2	4	2	4	2	4	4	2	4	2	4	2	4	4	4
Antibody detection	**Serum**[d]	4	8	4	8	4	8	8	4	8	4	8	4	1	1	1
	Time[e]	f	g	f	g	f	g	g	f	g	f	g	f	f	f	f

a, Challenged with SARS-CoV-2 in bronchus. b, Challenged with SARS-CoV-2 in both nose and bronchus. c, Swab. d, Number of samples. e, Days after infection. f, 1, 3, 5, and 7 days after infection. g, 1, 3, 5, 7, 9, 11, 13, and 15 days after infection.